J&J rises after guidance boost: plans to separate orthopaedics unit

[Top view image of text THIRD QUARTER on office desk.]
mohd izzuan

Johnson & Johnson (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) traded higher in the premarket on Tuesday after the New Brunswick, New Jersey-based company kicked off the healthcare earnings season, reporting better-than-expected results for Q3 2025 and raising its full-year sales outlook. [https://seekingalpha.com/news/4503798-johnson-johnson-reports-q3-results-raises-fy-guidance]

Concurrently, J&J (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) announced plans to separate its Orthopaedics division as a standalone unit named DePuy Synthes within 18–24 months in a bid to fast-track its MedTech portfolio’s shift toward higher-growth and higher-margin markets.

“This transaction enables Johnson & Johnson to further strengthen its focus and investment toward higher-growth areas where we can meaningfully extend and improve patient lives,” CEO Joaquin Duato remarked.

The company named Namal Nawana, a former CEO and a board member of U.K.-based MedTech company Smith & Nephew (SNN [https://seekingalpha.com/symbol/SNN]), as Worldwide President of DePuy Synthes, effective immediately. [https://seekingalpha.com/pr/20264057-johnson-and-johnson-announces-intent-to-separate-its-orthopaedics-business]

Nawana, who most recently served a privately held diagnostics company called Sapphiros as executive chairman and founder, will lead the separation process and will give leadership to DePuy once the transaction is complete, J&J (NYSE:JNJ [https://seekingalpha.com/symbol/JNJ]) said.

As for earnings, JNJ increased its full-year reported sales outlook to $93.5B–$93.9B, compared to $93.45B in the consensus and $93.2B–$93.6B projected in July. However, the company reiterated its adjusted full-year earnings outlook at $10.80–$10.90 per diluted share, compared to $10.85 in the consensus. [https://seekingalpha.com/pr/20264056-johnson-and-johnson-reports-q3-2025-results-raises-2025-sales-outlook]

MORE ON JOHNSON & JOHNSON

* Johnson & Johnson To Acquire Protagonist? It'd Be A Good Deal To Make [https://seekingalpha.com/article/4829332-johnson-and-johnson-to-acquire-protagonist-itd-be-good-deal-to-make]
* Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced [https://seekingalpha.com/article/4829076-johnson-and-johnson-safe-haven-quietly-becoming-overpriced]
* Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4825596-johnson-and-johnson-jnj-presents-at-bernstein-2nd-annual-global-healthcare-conference]
* Johnson & Johnson rises after reporting Q3 results, raises FY guidance [https://seekingalpha.com/news/4503798-johnson-johnson-reports-q3-results-raises-fy-guidance]
* Protagonist Therapeutics falls amid a report J&J deal price may be lower [https://seekingalpha.com/news/4503679-protagonist-therapeutics-falls-amid-a-report-jj-deal-price-may-be-lower]